Roivant, the drug developer founded by Republican Presidential candidate Vivek Ramaswamy, has sold the rights to its bowel disease treatment for $7.1 billion.
shares surged higher in pre-market trading after the Basel, Switzerland based drugmaker founded by Republican presidential candidate Vivek Ramaswamy agreed to sell the rights to a developing bowel disease drug it owns through a joint venture with Pfizer
Roivant holds around 75% of the joint-venture, with Pfizer owning the remaining 25% through a deal reached in 2022. “It has been a great privilege to work on and meaningfully progress RVT-3101, and we are convinced that Roche will be able to build on these efforts and maximize patient impact with this important program going forward," said Roivant CEO Matt Gline.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Vivek Ramaswamy wants Israel to be clear on war objectives before US support is grantedChris Irvine is managing editor of the Washington Examiner. He began his career across the pond at the Daily Telegraph in London in 2007, working on both the home news and foreign desks.
Read more »
Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 BillionSwiss pharmaceutical giant seeks to bolster pipeline
Read more »
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion‘Transformative transaction’ for Roivant gives Roche rights to promising inflammatory bowel disease treatment
Read more »
Ramaswamy Unsure About Participating in Third DebateBusinessman Vivek Ramaswamy has not decided if he will appear at the third Republican presidential debate, slated to occur in Miami, Florida, on No...
Read more »
Stocks extend slide, Chevron mega-deal, Apple slumps, 2-year auction on deck, Roivant drug saleStocks slide, Chevron mega-deal, Apple, 2-year auction, Roivant drug sale
Read more »
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Bln -- UpdateBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...
Read more »